sdAb-Saponin Conjugate for Targeted Cellular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery methods, such as antibody-drug conjugates (ADCs) and nucleic acid-based therapeutics, face challenges with off-target effects, poor specificity, and inefficient cellular uptake, leading to limited therapeutic efficacy and safety issues in treating diseases like cancer and autoimmune disorders.
Innovation Solution
A conjugate comprising a single-domain antibody (sdAb) covalently bound to a saponin, which can specifically target and transfer the saponin into cells, enhancing the therapeutic index of effector molecules by improving endosomal escape and reducing off-target toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody-drug conjugates (ADCs) are used for targeted delivery, then cell-specific delivery is improved, but off-target effects and toxicity remain significant
Solution Approach 1:
The invention divides the delivery system into two separate components: an antibody-saponin conjugate for targeted delivery and a separate effector molecule. This segmentation allows the delivery vehicle to be optimized for specificity while the effector can be optimized for potency, reducing off-target effects.
Solution Approach 2:
Saponin acts as an intermediary molecule that facilitates endosomal escape. The antibody-saponin conjugate delivers saponin to target cells, where saponin mediates the escape of therapeutic cargo from endosomes, improving delivery efficiency and reducing the need for high doses of potentially toxic effectors.
2Productivity
If high doses of therapeutic molecules are administered to achieve efficacy, then therapeutic effect is improved, but toxicity and side effects increase
Solution Approach 1:
The saponin component enables the system to self-enhance delivery through endosomal escape mechanisms, reducing dependence on high doses of external therapeutic agents. The conjugate utilizes cellular uptake pathways and saponin's inherent membrane-disrupting properties to achieve efficient intracellular delivery at lower doses.
Solution Approach 2:
The invention changes the delivery parameters by introducing saponin-mediated endosomal escape, which dramatically improves intracellular delivery efficiency. This parameter change allows achieving therapeutic effects at lower doses, thereby reducing toxicity.
3Reliability
If standard antibody conjugates are used, then targeted delivery is achieved, but endosomal escape efficiency is insufficient
Solution Approach 1:
The invention merges the targeted delivery capability of antibodies with the endosomal escape capability of saponins in a single conjugate molecule. This combination ensures both specific target cell recognition and efficient intracellular cargo release.
Solution Approach 2:
The antibody-saponin conjugate represents a composite molecular structure that combines the properties of antibodies (specific binding) and saponins (membrane interaction and endosomal escape), creating a material with dual functionality that overcomes the limitations of standard antibody conjugates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sdAb-saponin conjugate enables targeted delivery of therapeutic molecules into cells, widening the therapeutic window and reducing side effects, allowing for effective treatment at lower doses and improved efficacy in diseases like cancer and autoimmune disorders.
Implementation Method 1
a single-domain antibody (sdAb), capable of binding to said cell
Implementation Method 2
Conjugates of saponins with ligands... are capable of transporting said saponin from outside a cell to inside said cell
Implementation Method 3
enhancing the therapeutic index of effector molecules by improving endosomal escape
Data Source
AI summary
The invention relates to a conjugate for transferring a saponin of the monodesmosidic triterpene glycoside type or of the bidesmosidic triterpene glycoside type from outside a cell into said cell, the conjugate comprising a single-domain antibody, capable of binding to said cell, covalently bound to a saponin. The invention also relates to a pharmaceutical combination comprising a first pharmaceutical composition comprising the conjugate of the invention and a second pharmaceutical composition comprising an active pharmaceutical ingredient, or to a pharmaceutical composition comprising the conjugate of the invention and an active pharmaceutical ingredient. In addition, the invention relates to the pharmaceutical combination of the invention or the pharmaceutical composition of the invention, for use as a medicament, or for use in the treatment or the prophylaxis of a cancer, an auto-immune disease, an infection, an enzyme deficiency, a gene defect. Furthermore, the invention relates to an in vitro or ex vivo method for transferring a molecule from outside a cell to inside said cell, comprising the application of the conjugate of the invention. Finally, the invention relates to a kit of parts, comprising the pharmaceutical combination of the invention or the pharmaceutical composition of the invention, or the conjugate of the invention, and instructions for use thereof.